No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 6 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Virax Biolabs Group Limited (VRAX) stock was $2.03 as of Oct 6, 2026, 4:00 PM EDT, down 15.42% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -84.3% · 3-year avg -69.0%/yr
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Biotechnology · Lanarkshire, SC
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-1.75
Revenue Est.
$12423.00
Last Quarter Results
EPS
N/A
vs Estimate
$-1.50
Revenue
$12423.00
vs Estimate
$13893.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VRAX | $378,849 | $2.03 | -15.42% | -84.29% | N/A | N/A | N/A |
| 2NIKI | $403,887 | $4.96 | +4.89% | -97.86% | -71.40% | N/A | vs VRAX |
| 3XRTX | $481,786 | $1.73 | +1.76% | -57.33% | -63.52% | N/A | vs VRAX |
| 4SPRC | $250,443 | $4.33 | -0.69% | -89.69% | -82.56% | N/A | vs VRAX |
| 5VIVS | $518,606 | $0.20 | -2.18% | -93.85% | N/A | N/A | vs VRAX |
| 6HCWB | $545,796 | $1.57 | -4.27% | -93.15% | -69.71% | N/A | vs VRAX |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$2.03
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.50 | $-1.50 | $-1.50 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-6.00 | $-6.00 | $-6.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $13893.00 | $13893.00 | $13893.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $4000.00 | $4000.00 | $4000.00 | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
